More prescription coupons, discounts driving up costs, expert argues

Co-pay coupons and discounts offered to consumers ultimately will lead to higher costs across society as they increasingly drive up premiums, according to one leading expert on prescription drugs. » Read More

Coupons for brand-name drugs are misleading, experts say

At first, price-slashing discount coupons for expensive drugs may appeal to consumers on an everyday basis, but a look behind the scenes suggests that using brand-name medications may possibly yield little, if any, net savings. » Read More

Ayotte praised for role in driving opioid abuse legislation

Sen. Kelly Ayotte (R-NH) has been honored for her work in driving a bill through Congress aimed at battling the opioid, heroin and fentanyl abuse epidemic. » Read More

Report: Medicaid could save billions using pharmacy benefit management tools

Medicaid could see $51.1 billion over the next decade if a “full range of pharmacy benefit management tools” is employed, according to a new report completed by The Menges Group and released by the Pharmaceutical Care Management Association (PCMA). » Read More

U.S. patients pay less for Hepatitis C medication

Hepatitis C medication costs in 2015 proved lower for the U.S. than Europe and Japan, particularly prices negotiated by pharmacy benefit managers in Medicare Part D, the Pharmaceutical Care Management Association recently reported. » Read More

As debate rages, PBM sees big savings in biosimilars

As debate rages over drug prices, one of the country’s largest pharmacy benefit managers is touting biosimilars as a way of achieving significant savings over the next five years. » Read More

Express Scripts: Lack of competition led to price gouging on EpiPens

The experience of Mylan, the pharmaceutical company under fire for hiking the price of a life-saving allergy medicine, reinforces the importance of competition in the marketplace, one of the country’s largest pharmacy benefit managers said. » Read More

Survey: Most employers believe federal oversight would boost drug costs

Recent survey results conducted by North Star Opinion Research and released by an industry association confirm that 60 percent of U.S. employers believe new federal oversight would lead to higher prescription-drug costs. » Read More

Single industry-sponsored meal associated with increased brand-name prescriptions

A single industry-sponsored meal is enough to sway a doctor to prescribe a brand-name drug rather than a cheaper but just as effective generic, a study by the University of San Francisco has found. » Read More

Public opinion of drug makers lowest in 16 years, recent Gallup poll suggests

If drug manufacturers ever wonder whether they have a collective image problem, the answer is yes, according to a recent Gallup poll. » Read More

+ More News

Latest News

Napo launches Mytesi for HIV patients

Napo Pharmaceuticals has launched Mytesi, the only medication approved by the U.S. Food and Drug Administration for the relief of diarrhea in patients who have HIV. » Read More

Walgreens accepting donations to help Hurricane Matthew victims

Walgreens customers shopping in stores in the southeast United States can make donations to the American Red Cross Relief Fund to help the victims of Hurricane Matthew. » Read More

ACADIA named Pantheon DiNA Award recipient by CLSA

ACADIA Pharmaceuticals has been named the recipient of the 2016 Pantheon DiNA Award by the California Life Sciences Association for its therapeutic product NUPLAZID. » Read More

Pfizer combines of INLYTA trial data with pembrolizumab

Pfizer has released data from its Phase 1b clinical trial involving INLYTA, which has been combined with pembrolizumab, a PD-1 checkpoint inhibitor known as KEYTRUDA, in patients who have advanced renal cell carcinoma (RCC) that have yet to undergo treatment. » Read More

Pfizer releases SUTENT trial results

Pfizer has released results from its Phase 3 S-TRAC clinical study involving the assessment of SUTENT as an adjuvant therapy. » Read More

Vernalis begins promoting MOXATAG Tablets in U.S.

Vernalis Therapeutics Inc. has initiated its promotion of MOXATAG Tablets to primary care physicians in the United States. » Read More

Supernus reports positive topline results for SPN-182 clinical trial

Supernus Pharmaceuticals' Phase IIb clinical trial involving SPN-812 to determine dosing ranges has turned in positive topline results for the treatment of attention deficit hyperactivity disorder (ADHD) in children. » Read More

FDA accepts KenPharm’s IND application for ADHD prodrug

The U.S. Food and Drug Administration has accepted KenPharm's Investigational New Drug application for KP415, the company’s extended release d-threomethylphenidate prodrug that was developed to treat attention deficit hyperactivity disorder. » Read More

CymaBay Therapeutics has received a patent to treat NAFLD

CymaBay Therapeutics has received a patent to treat NAFLD and NASH with MBX-0825 by administering an amount that proves to be therapeutically effective orally. » Read More

FDA approves Lundbeck’s Carnexiv injection

Lundbeck's Carnexiv injection -- an orally administered replacement therapy for short-term use to treat adults with specific types of seizures -- has been approved by the U.S. Food and Drug Administration. » Read More

+ More News